California -based bio’s established cell therapy platforms. Gritstone Oncology has struck a deal with Grtistone biotechnology company bluebird bio, in order to develop cell therapy cancer treatments. Gritstone Oncology will use its proprietary EDGE AI platform to identify and supply 10 tumor-specific targets, as well as selected natural T-cell receptors, which bluebird bio will then use in its cell therapy platforms. California will receive $10m up-front funding and $20m in series C preferred equity investment as part of the agreement.
California -based Gritstone Oncology has struck a deal with Grtistone biotechnology company bluebird bio, in order to develop cell therapy cancer treatments. Gritstone Oncology will use its proprietary EDGE AI platform to identify and supply 10 tumor-specific targets, as well as selected natural T-cell receptors, which bluebird bio will then use in its cell therapy platforms. California will receive $10m up-front funding and $20m in series C preferred equity investment as part of the agreement.